Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

PRIMARY OBJECTIVES: I. To evaluate the toxicity of the combination of sapanisertib and nivolumab in patients with advanced non-small cell lung cancer (NSCLC) who have had disease progression on prior PD-1/PD-L1 inhibitor therapy. II. To confirm recommended phase 2 dose (RP2D) of the combination of sapanisertib and nivolumab in patients with advanced NSCLC who have had disease progression on prior PD-1/PD-L1 inhibitor therapy. III. To estimate the objective response rate of the combination of sapanisertib and nivolumab in patients with advanced NSCLC who have had disease progression on prior PD-1/PD-L1 inhibitor therapy. SECONDARY OBJECTIVES: I. To determine progression free survival (PFS) of the combination of sapanisertib and nivolumab in patients with advanced NSCLC who have had disease progression on prior PD-1/PD-L1 inhibitor therapy. II. To determine overall survival (OS) of the combination of sapanisertib and nivolumab in patients with advanced NSCLC who have had disease progression on prior PD-1/PD-L1 inhibitor therapy. III. To estimate the disease control rate of the combination of sapanisertib and nivolumab in patients with advanced NSCLC who have had disease progression on prior PD-1/PD-L1 inhibitor therapy. IV. To determine if there are drug-drug interaction (DDI) for the combination of sapanisertib and nivolumab. EXPLORATORY OBJECTIVES: I. To compare gene and protein expression in pre-treatment and on-treatment tumor samples. II. To compare gene and protein expression in tumor samples of responders and nonresponders. III. To compare immune cell infiltration and immune markers in pre-treatment and on-treatment tumor samples. IV. To compare immune cell infiltration and immune markers in tumor samples of responders and non-responders. V. To correlate clinical outcomes with tumor mutational burden and cancer gene mutations detected by molecular profiling. VI. To compare gene expression at the single-cell level in pre-treatment and on-treatment tumor samples. VII. To compare gene expression at the single-cell level in tumor samples of responders and non-responders. VIII. To compare cell-free deoxyribonucleic acid (DNA) levels in pre-treatment, on-treatment, and at progression tumor samples. OUTLINE: Patients receive sapanisertib orally (PO) once daily (QD) on days 1, 8, 15, and 22 and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.